Compare BICO Group AB with Similar Stocks
Dashboard
1
With a fall in Net Sales of -12.39%, the company declared Very Negative results in Dec 25
- OPERATING CASH FLOW(Y) Lowest at SEK 68.4 MM
- PRE-TAX PROFIT(Q) At SEK -50.4 MM has Fallen at -119.38%
- NET PROFIT(Q) At SEK -52.7 MM has Fallen at -120.02%
2
Risky -
3
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
SEK 1,206 Million (Small Cap)
NA (Loss Making)
NA
0.00%
-0.12
-30.06%
0.69
Revenue and Profits:
Net Sales:
451 Million
(Quarterly Results - Dec 2025)
Net Profit:
-59 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-7.68%
0%
-7.68%
6 Months
-15.1%
0%
-15.1%
1 Year
-48.86%
0%
-48.86%
2 Years
-59.27%
0%
-59.27%
3 Years
-68.35%
0%
-68.35%
4 Years
-89.18%
0%
-89.18%
5 Years
-95.49%
0%
-95.49%
BICO Group AB for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
59.80%
EBIT Growth (5y)
-208.18%
EBIT to Interest (avg)
-2.40
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.18
Sales to Capital Employed (avg)
0.48
Tax Ratio
2.33%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
1.56%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.67
EV to EBIT
-8.32
EV to EBITDA
34.60
EV to Capital Employed
0.73
EV to Sales
1.21
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-8.72%
ROE (Latest)
-16.27%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
No Trend
Bearish
Shareholding Snapshot : Dec 2025
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 2 Foreign Institutions (1.56%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY
Dec'25
Dec'24
Change(%)
Net Sales
451.30
515.10
-12.39%
Operating Profit (PBDIT) excl Other Income
40.60
104.10
-61.00%
Interest
42.20
26.90
56.88%
Exceptional Items
-8.60
-5.30
-62.26%
Consolidate Net Profit
-59.20
250.50
-123.63%
Operating Profit Margin (Excl OI)
-34.30%
-22.50%
-1.18%
USD in Million.
Net Sales
YoY Growth in quarter ended Dec 2025 is -12.39% vs 29.72% in Dec 2024
Consolidated Net Profit
YoY Growth in quarter ended Dec 2025 is -123.63% vs 156.52% in Dec 2024
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
1,497.20
1,727.20
-13.32%
Operating Profit (PBDIT) excl Other Income
-17.80
81.10
-121.95%
Interest
68.20
96.60
-29.40%
Exceptional Items
-1,066.00
-134.20
-694.34%
Consolidate Net Profit
-1,583.80
-110.00
-1,339.82%
Operating Profit Margin (Excl OI)
-157.00%
-118.10%
-3.89%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is -13.32% vs -14.09% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -1,339.82% vs 86.05% in Dec 2024
About BICO Group AB 
BICO Group AB
Pharmaceuticals & Biotechnology
Cellink AB is a Sweden-based company, which is primarily involved in the healthcare industry. The Company operates as a provider of advanced bioprinting solutions for healthcare sector. The Company offers 3D bioprinting of human tissues and organs. The Company's technology facilitates the biofabrication of cell-laden anatomical structures with controlled cell density and homogenous distribution of viable cells. The cell-laden bioink structures are then cultured in vitro, under controlled conditions for a wide range of experiments. In addition, bioprinting with human cells can be combined with computer-aided design (CAD) and computer-aided manufacturing (CAM) using medical images from CT or MRI scans to create a blueprint (3D model) for bioprinting of patient-specific tissues and organs.
Company Coordinates 
Company Details
Arvid Wallgrens Backe 20 , GOETEBORG None : 413 46
Registrar Details






